Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 3
2020 6
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.
Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, Walling D, Weiser M, Harvey PD, Strauss GP, Luthringer R. Davidson M, et al. Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013. Schizophr Bull. 2022. PMID: 35211743 Free PMC article. Clinical Trial.
This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population. METHODS: Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia w …
This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population. METHODS: …
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. Lobo MC, et al. Neurosci Biobehav Rev. 2022 Jan;132:324-361. doi: 10.1016/j.neubiorev.2021.11.032. Epub 2021 Nov 24. Neurosci Biobehav Rev. 2022. PMID: 34838528 Review.
Lu AF35700 (dopamine and serotonin receptor antagonist) was tested in treatment-resistance with no positive results. Pimavanserin, roluperidone, ulotaront and xanomeline do not act directly on the D2 receptor at clinical doses. Initial studies indicate pimavanserin and …
Lu AF35700 (dopamine and serotonin receptor antagonist) was tested in treatment-resistance with no positive results. Pimavanserin, rolupe …
Long-term effects of Roluperidone on negative symptoms of schizophrenia.
Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, Harvey PD, Luthringer R. Rabinowitz J, et al. Schizophr Res. 2023 May;255:9-13. doi: 10.1016/j.schres.2023.03.028. Epub 2023 Mar 16. Schizophr Res. 2023. PMID: 36933291 Free article.
Roluperidone has antagonist properties for 5-HT(2A), sigma(2), alpha(1A)- and alpha(1B)-adrenergic receptors, but no dopaminergic binding affinities. ...Overall rate of symptomatic worsening requiring discontinuation of roluperidone and treatment with an antipsychot …
Roluperidone has antagonist properties for 5-HT(2A), sigma(2), alpha(1A)- and alpha(1B)-adrenergic receptors, but no dopaminergic bin …
Structures of the σ2 receptor enable docking for bioactive ligand discovery.
Alon A, Lyu J, Braz JM, Tummino TA, Craik V, O'Meara MJ, Webb CM, Radchenko DS, Moroz YS, Huang XP, Liu Y, Roth BL, Irwin JJ, Basbaum AI, Shoichet BK, Kruse AC. Alon A, et al. Nature. 2021 Dec;600(7890):759-764. doi: 10.1038/s41586-021-04175-x. Epub 2021 Dec 8. Nature. 2021. PMID: 34880501 Free PMC article.
Here we determined the crystal structure of this receptor in complex with the clinical candidate roluperidone(2) and the tool compound PB28(8). These structures templated a large-scale docking screen of 490 million virtual molecules, of which 484 compounds were synthesized …
Here we determined the crystal structure of this receptor in complex with the clinical candidate roluperidone(2) and the tool compoun …
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression.
Harvey PD, Saoud JB, Luthringer R, Moroz S, Blazhevych Y, Stefanescu C, Davidson M. Harvey PD, et al. Schizophr Res. 2020 Jan;215:352-356. doi: 10.1016/j.schres.2019.08.029. Epub 2019 Sep 2. Schizophr Res. 2020. PMID: 31488314 Clinical Trial.
The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. METHODS: This was a multi-national Phase 2b trial that enrolled 244 symptomatically stable patients with schizophrenia who had baseline scores 20 on …
The objective here is to explore the effect of roluperidone compared to placebo, on the 2 domains of the Negative Symptoms. METHODS: …
Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial.
Strauss GP, Zamani Esfahlani F, Sayama H, Kirkpatrick B, Opler MG, Saoud JB, Davidson M, Luthringer R. Strauss GP, et al. Schizophr Bull. 2020 Jul 8;46(4):964-970. doi: 10.1093/schbul/sbz141. Schizophr Bull. 2020. PMID: 31989151 Free PMC article. Clinical Trial.
However, it is unclear how the drug achieved its effect from a network perspective. The current study evaluated the efficacy of roluperidone from a network perspective. In this randomized clinical trial, participants with schizophrenia and moderate to severe negative sympt …
However, it is unclear how the drug achieved its effect from a network perspective. The current study evaluated the efficacy of roluperid …
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial.
Rabinowitz J, Badescu S, Palamarchuk P, Filyk V, Voloshchuk A, Rud V, Melnyk E, Skrypnikov A, Davidson M, Saoud J, Luthringer R. Rabinowitz J, et al. Schizophr Res. 2019 Sep;211:103-104. doi: 10.1016/j.schres.2019.07.029. Epub 2019 Jul 30. Schizophr Res. 2019. PMID: 31375316 Clinical Trial. No abstract available.
Beyond dopamine: Novel strategies for schizophrenia treatment.
Dudzik P, Lustyk K, Pytka K. Dudzik P, et al. Med Res Rev. 2024 Apr 23. doi: 10.1002/med.22042. Online ahead of print. Med Res Rev. 2024. PMID: 38653551 Review.
Finally, we evaluate the 5-HT(2A) antagonist paradigm, assessing two recently developed serotonergic agents, pimavanserin and roluperidone. We present the latest advancements in developing novel solutions to the complex challenges posed by schizophrenia, offering an additi …
Finally, we evaluate the 5-HT(2A) antagonist paradigm, assessing two recently developed serotonergic agents, pimavanserin and roluperidon …
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.
Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Ľupták M, et al. World J Psychiatry. 2021 Jul 19;11(7):277-296. doi: 10.5498/wjp.v11.i7.277. eCollection 2021 Jul 19. World J Psychiatry. 2021. PMID: 34327122 Free PMC article. Review.
Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, agonists of trace amine-associated receptor 1, inhibitors of glycine transporters, AMPA allosteric modulators, mGLUR(2-3) agonists, D-amino a …
Substances with promising results in preclinical and clinical studies include lumateperone, pimavanserin, xanomeline, roluperidone, a …
19 results